MentionFox
Home › funding signals › Modulari-T
Accelerator · announced

Modulari-T (YC W23) — We teach your immune system to attack and cure cancer

Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise. Modulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly.

Modulari-T is a Y Combinator company in the Winter 2023 batch. Its directory entry describes it as: We teach your immune system to attack and cure cancer. The founders listed are David White (Founder), Stephanie Mok (Founder) (Y Combinator directory entry, January 31, 2023).

6 more companies from YC Winter 2023 ↓

Run the free check on Modulari-T →

Sell to companies like Modulari-T? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Modulari-T

New accelerator entry · 2023-01-31 · the record

Winter 2023
batch
4
people
Early
stage
Canada
region
Open the record →

What the record says

BatchWinter 2023
Announced2023-01-31
StageEarly
StatusActive
Team size4
IndustryHealthcare
Sub-industryHealthcare -> Therapeutics
SectorsGene Therapy, Cell Therapy, Synthetic Biology, Biotech, Oncology
RegionsCanada, United States of America, America / Canada
BasedMontreal, Canada
HiringNo
Sitehttps://modularit.bio
Founded2021
Previously known asModulari-T Biosciences

Pitching, partnering or investing alongside them? See who really runs and owns Modulari-T.

Free to see. No signup.

Keep reading

More on Modulari-T and the records around it.

What do you want to do with Modulari-T?

Get the full cited report on Modulari-T

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Modulari-T: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

In their words

Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise. Modulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue. Modulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.

Want the whole picture on Modulari-T?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Modulari-T: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Modulari-T covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Modulari-T: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.

Sourced from the company's Y Combinator directory entry.

RSS

Tools for this story

Each opens in a new tab, filled in for Modulari-T. With no account yet, you sign up free and land on the result.

On these startup lists

Biotech startups

Share this page

Is this your company?

Share the news. Sharing needs no account.

Modulari-T: Accepted into Y Combinator Winter 2023
Share on LinkedIn Share on X Download image

Cite this page

Permanent URL: https://mentionfox.com/funding/yc-modulari-t
Last updated 2026-10-27
Primary record: Y Combinator directory entry
Modulari-T (YC W23) — We teach your immune system to attack and cure cancer. MentionFox, 2026-10-27. https://mentionfox.com/funding/yc-modulari-t